Search results: “Arg”

Chao-Tsung Yang, Ph.D., Principal Scientist Group Leader R&D Department Eurofins DiscoverX, Fremont, CA

With the increasing industry focus on antibody drugs, there is an ever-greater need for functional bioassays that interrogate the therapeutic…

The development of antibody-based therapeutics to target the killing of tumor cells has revolutionized the space of immuno-oncology and the…

Fast Cell-Based Assays for the Detection of Protein Turnover

View validation data for diverse kinases. Cellular target engagement potency data for multiple kinase inhibitors Dose response curves for under-studied…

GLP Cell Lines & Ready-to-Use Assays from Characterization through QC Lot Release

Comprehensive Eurofins DiscoverX product list to enable your drug discovery and development programs focused on checkpoint receptors, cytokine receptors/interleukins, cytotoxicity,…

Cytokines play a crucial role in immune responses and have become important drug targets for treating inflammatory and autoimmune diseases.

Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders.…

Checkpoint blockade antibodies are established cancer therapeutics. However, in recent years, agonistic antibodies have emerged as therapeutics not only for…

Case studies on the characterization & clinical development of agonistic antibody therapeutics targeting checkpoint receptors.

A series of substituted indoles were examined as selective inhibitors of tropomyosin-related kinase receptor A (TrkA), a therapeutic target for…